PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsLevodopa
Larodopa, Stalevo(levodopa)
Carbidopa / / Levodopa, Carbidopa / Levodopa, Corbilta, Crexont, Dhivy, Duopa, Inbrija, Levodopa/Carbidopa/Entacapone, Numient, Rytary, Sinemet, Stalevo (levodopa) is a small molecule pharmaceutical. Levodopa was first approved as Sinemet on 1982-01-01. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. It is known to target G-protein coupled receptor 143.
Download report
Favorite
Novartis Pharmaceuticals
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
Trade Name
FDA
EMA
Inbrija (discontinued: Bendopa, Dopar, Larodopa)
Combinations
Carbidopa levodopa, Carbidopa, levodopa entacapone, Crexont, Dhivy, Duopa, Rytary, Sinemet, Stalevo (discontinued: Carbidopa levodopa, Carbidopa, levodopa entacapone, Carbilev, Parcopa, Sinemet)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levodopa
Tradename
Company
Number
Date
Products
INBRIJAMerzN-209184 RX2018-12-21
1 products, RLD, RS
Show 3 discontinued
Carbidopa
+
Levodopa
Tradename
Company
Number
Date
Products
DUOPAAbbVieN-203952 RX2015-01-09
1 products, RLD, RS
DHIVYAvion PharmaceuticalsN-214869 RX2021-11-12
1 products, RLD, RS
RYTARYImpax LaboratoriesN-203312 RX2015-01-07
4 products, RLD, RS
CREXONTImpax LaboratoriesN-217186 RX2024-08-07
4 products, RLD, RS
SINEMETOrganonN-017555 RX1982-01-01
3 products, RLD
Show 1 discontinued
Carbidopa
+
Entacapone
+
Levodopa
Tradename
Company
Number
Date
Products
STALEVO 50Orion PharmaN-021485 RX2003-06-11
1 products, RLD, RS
STALEVO 100Orion PharmaN-021485 RX2003-06-11
1 products, RLD
STALEVO 150Orion PharmaN-021485 RX2003-06-11
1 products, RLD
STALEVO 200Orion PharmaN-021485 RX2007-08-02
1 products, RLD, RS
STALEVO 75Orion PharmaN-021485 RX2008-08-29
1 products, RLD
STALEVO 125Orion PharmaN-021485 RX2008-08-29
1 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
carbidopa and levodopaANDA2025-03-14
carbidopa, levodopa and entacaponeANDA2022-02-01
carbidopa, levodopa, and entacaponeNDA authorized generic2016-02-01
carbidopa-levodopaANDA2025-01-29
crexontNew Drug Application2024-08-07
dhivyNew Drug Application2024-01-31
duopaNew Drug Application2022-03-04
inbrijaNew Drug Application2024-12-12
parcopa2007-11-05
rytaryNew Drug Application2022-12-21
Show 2 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
parkinson diseaseEFO_0002508D010300G20
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Carbidopa / Levodopa, Dhivy, Avion Pharms
110335212039-03-28DPU-219, U-3304, U-3305
114396132039-03-28U-3557
Levodopa, Inbrija, Acorda
85458782032-11-16DP
86854422032-11-16DP
89456122032-11-16DP
93932102032-11-16DP
RE437112029-02-03U-2484
71829612024-02-22DP
84042762023-03-19U-2484
85860932023-03-19U-2484
91556992023-03-19DP
Carbidopa / Levodopa, Rytary, Impax Labs Inc
83774742028-12-26DPU-219, U-1645
84549982028-12-26DPU-219, U-1645, U-1646, U-1647, U-1649
85572832028-12-26DPU-219, U-1645
90896072028-12-26DPU-1645, U-1720
90896082028-12-26DP
94632462028-12-26DPU-219
95330462028-12-26DPU-219
99016402028-12-26DPU-219
ATC Codes
N: Nervous system drugs
— N04: Anti-parkinson drugs
— N04B: Dopaminergic agents
— N04BA: Dopa and dopa derivatives
— N04BA01: Levodopa
— N04BA02: Levodopa and decarboxylase inhibitor
— N04BA03: Levodopa, decarboxylase inhibitor and comt inhibitor
HCPCS
Code
Description
J7340
Carbidopa 5 mg/levodopa 20 mg enteral suspension, 100 ml
Clinical
Clinical Trials
671 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G207513711749127475
DyskinesiasD020820—G248421331473
Healthy volunteers/patients———13——4219
DepressionD003863—F33.911—6614
Depressive disorderD003866EFO_1002014F32.A—2—6210
StrokeD020521EFO_0000712I63.9123329
Cognitive dysfunctionD060825—G31.84—2—215
Major depressive disorderD003865EFO_0003761F22—1—225
DementiaD003704EFO_0003862F031——124
Neurologic gait disordersD020233—R26.1—1—124
Show 31 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GliomaD005910EFO_0000520—432—514
Drug-induced dyskinesiaD004409EFO_1000904——73—311
Brain neoplasmsD001932EFO_0003833C71111—811
HyperinsulinismD006946—E16.1142—29
SyndromeD013577——233—18
Cocaine-related disordersD019970—F14161—18
Congenital hyperinsulinismD044903——132—28
NesidioblastosisD046768EFO_0007318E16.9132—28
Neuroendocrine tumorsD018358EFO_1001901D3A.8—12—47
LeukemiaD007938—C95112——4
Show 21 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Movement disordersD009069EFO_0004280G2538——313
Parkinsonian disordersD020734—G20.C45——513
GlioblastomaD005909EFO_0000515—34——310
Macular degenerationD008268EFO_0001365H35.3016——29
Shy-drager syndromeD012791EFO_1001050—21——79
Multiple system atrophyD019578——21——79
Nervous system diseasesD009422—G00-G9913——37
SchizophreniaD012559EFO_0000692F2021——47
RecurrenceD012008——21——36
AtrophyD001284——12——46
Show 50 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neoplasm metastasisD009362EFO_0009708—2———57
Pure autonomic failureD054970——2———24
Diabetic retinopathyD003930EFO_0003770—2————2
AlcoholismD000437EFO_0003829F10.11———12
InsulinomaD007340——1———12
GliosarcomaD018316——1———12
EpendymomaD004806——1———12
AstrocytomaD001254EFO_0000271—1———12
OligodendrogliomaD009837EFO_0000631—1———12
Myelodysplastic syndromesD009190—D461————1
Show 47 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Progressive supranuclear palsyD013494EFO_0002512G23.1————44
DystoniaD004421——————33
Huntington diseaseD006816Orphanet_399G10————22
Corticobasal degenerationD000088282—G31.85————22
Diet therapyD004035——————22
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.9————22
Lung diseasesD008171EFO_0003818J98.4————22
NarcolepsyD009290EFO_0000614G47.4————11
Carcinoid tumorD002276—D3A.00————11
Glucose intoleranceD018149HP_0000833R73.03————11
Show 50 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLevodopa
INNlevodopa
Description
L-dopa is an optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease It has a role as a prodrug, a hapten, a neurotoxin, an antiparkinson drug, a dopaminergic agent, an antidyskinesia agent, an allelochemical, a plant growth retardant, a human metabolite, a mouse metabolite and a plant metabolite. It is a dopa, a L-tyrosine derivative and a non-proteinogenic L-alpha-amino acid. It is a conjugate acid of a L-dopa(1-). It is an enantiomer of a D-dopa. It is a tautomer of a L-dopa zwitterion.
Classification
Small molecule
Drug classdopamine receptor agonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O
Identifiers
PDB—
CAS-ID59-92-7
RxCUI—
ChEMBL IDCHEMBL1009
ChEBI ID15765
PubChem CID6047
DrugBankDB01235
UNII ID46627O600J (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Inbrija – Acorda Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Sinemet – Organon
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Rytary – Amneal Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Duopa – AbbVie
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Levodopa
+
Entacapone
+
Carbidopa
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Levodopa
+
Carbidopa
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 42,281 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
67,689 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use